Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the purchase, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) traded up 1.49% during trading on Tuesday, reaching $14.35. 7,120,909 shares of the company’s stock traded hands. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $32.74. The company has a 50-day moving average of $16.09 and a 200 day moving average of $13.39. The stock’s market capitalization is $5.00 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same period in the previous year, the business earned ($0.88) earnings per share. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities research analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Valeant Pharmaceuticals International, Inc. (VRX) Director Acquires 10,000 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/22/insider-buying-valeant-pharmaceuticals-international-inc-vrx-director-acquires-10000-shares-of-stock.html.

A number of analysts recently weighed in on VRX shares. Scotiabank decreased their price target on shares of Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 26th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $19.00 price target (up previously from $18.00) on shares of Valeant Pharmaceuticals International in a research note on Thursday, May 4th. Wells Fargo & Company reiterated an “underperform” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, May 5th. Jefferies Group LLC set a $18.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Saturday, May 6th. Finally, J P Morgan Chase & Co reiterated a “hold” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, May 9th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $17.81.

Large investors have recently modified their holdings of the company. Gruss & Co. Inc. acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at approximately $104,000. Financial Architects Inc boosted its stake in shares of Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at approximately $110,000. WMS Partners LLC acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at approximately $116,000. Finally, Brave Asset Management Inc. acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at approximately $119,000. Hedge funds and other institutional investors own 50.96% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Insider Buying and Selling by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.